MAPT and Alzheimer disease: Among the 13 studies included in our analysis, Nam [32]and Perrott [41]et al. believed that neurogenic exosome Aβ42 was not significantly different between the AD group and control group, while Perrott [41] believed that neurogenic exosome T-tau was not significantly different between the AD group and control group.